2023
Cerebral Embolic Protection in Transcatheter Aortic Valve Replacement
Iskander M, Jamil Y, Forrest J, Madhavan M, Makkar R, Leon M, Lansky A, Ahmad Y. Cerebral Embolic Protection in Transcatheter Aortic Valve Replacement. Structural Heart 2023, 7: 100169. PMID: 37520138, PMCID: PMC10382985, DOI: 10.1016/j.shj.2023.100169.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementCerebral embolic protection devicesCerebral embolic protectionAortic valve replacementEmbolic protection devicesValve replacementEmbolic protectionSymptomatic severe aortic stenosisSevere aortic stenosisLow-risk patientsPredictors of strokeOccurrence of complicationsRisk of strokeRecent trial dataRelevant clinical studiesOverall evidence baseExpansion of TAVRFeared complicationAortic stenosisSurgical riskTreatment optionsWorse outcomesClinical studiesPatientsTrial data
2019
Clinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent
Saito Y, Baumbach A, Wijns W, Xu B, Kelbæk H, Zheng M, Morel M, Anderson R, Schächinger V, Lansky A, Investigators T. Clinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent. Catheterization And Cardiovascular Interventions 2019, 96: 1023-1028. PMID: 31769161, DOI: 10.1002/ccd.28609.Peer-Reviewed Original ResearchConceptsHigh-risk patientsClinical outcomesComer studyI trialDurable polymer everolimus-eluting stentsTarget vessel myocardial infarctionSirolimus-eluting coronary stentYear clinical outcomesTarget lesion failureVessel myocardial infarctionLow-risk patientsWorse clinical outcomesEverolimus-eluting stentsHigh-risk groupLow-risk groupStrict eligibility criteriaFIREHAWK stentLesion failurePrimary endpointRandomized trialsMyocardial infarctionRisk groupsInclusion criteriaComplex lesionsXIENCE stent
2012
Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome
Boden WE, Lansky A, Angiolillo DJ. Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. The American Journal Of Cardiology 2012, 111: 439-444. PMID: 23168289, DOI: 10.1016/j.amjcard.2012.10.018.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeDual antiplatelet therapyAntiplatelet therapyCoronary syndromeHigh-risk percutaneous coronary interventionUnmet needPotent platelet inhibitionChronic kidney diseaseComplex coronary anatomyFirst-line therapyHigh-risk patientsLow-risk patientsPercutaneous coronary interventionSubgroup of patientsPrevious revascularizationPharmacologic managementCoronary interventionRisk patientsDiabetes mellitusPlatelet inhibitionSuch patientsCoronary anatomyKidney diseaseTherapeutic optionsTreatment options
2006
Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: Analysis from the CADILLAC trial
Brodie BR, Stone GW, Cox DA, Stuckey TD, Turco M, Tcheng JE, Berger P, Mehran R, McLaughlin M, Costantini C, Lansky AJ, Grines CL. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: Analysis from the CADILLAC trial. American Heart Journal 2006, 151: 1231-1238. PMID: 16781224, DOI: 10.1016/j.ahj.2005.07.016.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPercutaneous coronary interventionAcute myocardial infarctionLow-risk patientsLeft ventricular functionOnset of symptomsTreatment delayCoronary interventionEarly reperfusionMyocardial infarctionCADILLAC trialVentricular functionComplete ST-segment resolutionPercutaneous transluminal coronary angioplastyFrequent grade 2ST-segment resolutionHigh-risk patientsSuperior clinical outcomesTransluminal coronary angioplastyMicrovascular reperfusionBalloon timeCoronary angioplastyClinical outcomesMyocardial blushPatient triage